Form 4: Amphastar Pharmaceuticals Director Howard Lee Reports Equity Compensation and Tax-Related Share Disposition

Amphastar Pharmaceuticals Director Howard Lee reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax withholding purposes, as detailed in a recent SEC Form 4 filing.

Summary

• Director Howard Lee of Amphastar Pharmaceuticals, Inc. (AMPH) reported equity transactions on June 2 and June 3, 2025.
• On June 2, 2025, Mr. Lee acquired 5,122 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0, which are scheduled to vest on June 2, 2026.
• Concurrently on June 2, 2025, Mr. Lee also acquired 11,402 stock options at a price of $0, with an exercise price of $25.38; these options will vest on June 2, 2026, and expire on June 2, 2035.
• On June 3, 2025, 923 shares of Common Stock were disposed of at a price of $26.01 per share to satisfy tax liabilities associated with the vesting of RSUs.
• Following these transactions, Mr. Lee's direct beneficial ownership of Common Stock stands at 151,976 shares, in addition to 11,402 stock options.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director is acquiring additional equity (RSUs and stock options), aligning their interests with shareholders. The disposition of shares is for tax purposes, which is a routine and neutral event.

Positives

• Director Howard Lee acquired 5,122 Restricted Stock Units (RSUs) and 11,402 stock options, indicating continued equity participation and alignment with shareholder interests.
• The acquisition of RSUs and stock options at a $0 price suggests these are likely part of compensation, aligning management incentives with company performance.

Negatives

• 923 shares of Common Stock were disposed of to cover tax liabilities associated with RSU vesting, which is a common practice but reduces the director's direct shareholding.

Future Outlook

The acquired Restricted Stock Units (RSUs) and stock options are scheduled to vest on June 2, 2026, indicating future equity realization for the director. The stock options have an expiration date of June 2, 2035.

Industry Context

This Form 4 filing details routine insider equity transactions for a director at Amphastar Pharmaceuticals, Inc. Such filings are standard disclosures for publicly traded companies and reflect individual executive compensation and ownership changes rather than broader industry trends.

Stakeholder Impact

• Shareholders: The acquisition of equity by a director may be viewed positively as it aligns management's interests with shareholder value creation.

Next Steps

• Vesting of 5,122 Restricted Stock Units (RSUs) on June 2, 2026.
• Vesting of 11,402 stock options on June 2, 2026.
• Potential exercise of stock options by June 2, 2035.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, SEC Form 4, Insider Trading, Director Compensation, Restricted Stock Units, Stock Options, Equity Ownership, Executive Compensation